Abstract:Background Non‐alcoholic fatty liver disease (NAFLD) is associated with high cardiovascular morbidity/mortality, including heart failure. Abnormalities in left ventricular (LV) structure/function are associated with heart failure risk. Methods and Results Participants from the population‐based CARDIA (Coronary Artery Risk Development in Young Adults) study year 25 exam (2010–2011, aged 43–55 years, 61% women, 48% black) with computed tomography measured liver fat and comprehensive echocardiography were included. Echocardiography was repeated at year 30 follow‐up (aged 47–62 years, N=1827). NAFLD was defined as liver attenuation ≤40 HU after exclusions. LV geometry was classified into normal and abnormal by integrating relative wall thickness and LV mass index. Diastolic function was defined using Doppler and tissue Doppler imaging. Systolic function was assessed with myocardial strain measured by speckle tracking. NAFLD prevalence was 8.7% (n=159). NAFLD participants had higher LV mass, relative wall thickness, incident LV hypertrophy and abnormal LV geometry versus non‐NAFLD ( P <0.02). NAFLD participants had impaired LV relaxation (E/A ratio 1.1 versus 1.2), higher LV filling pressures (E/e′ ratio 7.9 versus 7.2), worse longitudinal strain (−13.9% versus −15.3%), and lower LV ejection fraction (58.9% versus 60.2%, P <0.01). In multivariable analyses adjusted for heart failure risk factors, NAFLD was independently associated with incident LV hypertrophy (odds ratio: 1.9, 95% CI: 1.1–3.4), abnormal LV geometry (odds ratio: 1.9, 1.1–3.3) and greater change in strain (odds ratio: 2.2, 1.1–4.7). Adjustment for body mass index attenuated associations to non‐significance. Conclusions NAFLD is associated with subclinical changes over time in LV structure/function and obesity explains much of the association. Presence of obesity in mid‐life may identify an important at‐risk population in whom to focus preventive heart failure strategies. Clinical Perspective What Is New? Non‐alcoholic fatty liver disease (NAFLD) is cross‐sectionally associated with subclinical myocardial dysfunction. Whether NAFLD is prospectively associated with short‐term changes in myocardial dysfunction is unknown. This study investigates whether computed tomography‐defined NAFLD is associated with 5‐year changes in echocardiographic markers of subclinical heart failure among middle aged adults in the CARDIA (Coronary Artery Risk Development in Young Adults) study. What Are the Clinical Implications? Study findings indicate that NAFLD is associated with incident left ventricular hypertrophy, abnormal left ventricular geometry and worsening myocardial strain over a 5‐year period independent of traditional heart failure risk factors and change in body mass index. Obesity explains much of the association between NAFLD and changes in myocardial structure/function. Diagnosis of asymptomatic NAFLD in middle age may be a previously unrecognized risk marker for left ventricular remodeling over time. Introduction Heart failure (HF) and non‐alcoholic fatty liver disease (NAFLD) are obesity‐related conditions with high cardiovascular disease (CVD) morbidity and mortality that have reached epidemic proportions. 1 , 2 , 3 Evidence suggests that NAFLD is an independent risk factor for CVD. 4 , 5 , 6 , 7 , 8 , 9 , 10 In fact, patients with NAFLD are more likely to die from complications of CVD than from liver disease. 11 We, and others, have demonstrated a cross‐sectional association between NAFLD and subclinical myocardial remodeling and function independent of established HF risk factors, providin -Abstract Truncated-

VLDL triglycerides and cholesterol in non-alcoholic fatty liver disease and myocardial infarction

Positive Relationship Between Serum Low-Density Lipoprotein Cholesterol Levels and Visceral Fat in a Chinese Nondiabetic Population.

Estimated Small Dense Low‐density Lipoprotein Cholesterol and Nonalcoholic Fatty Liver Disease in Nonobese Populations

Remnant Cholesterol Independently Predicts the Development of Nonalcoholic Fatty Liver Disease

Association Between High-Density Lipoprotein Cholesterol to Apolipoprotein A-I Ratio and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study

TG/HDL-C Ratio is Positively Associated with Risk and Severity of CHD among NAFLD Patients: a Case Control Study

Non-alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study

Mediating role of atherogenic lipoproteins in the relationship between liver fat and coronary artery calcification

Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort

Elevated low-density lipoprotein cholesterol: An inverse marker of morbidity and mortality in patients with myocardial infarction

Increased levels of low-density lipoprotein cholesterol within the normal range as a risk factor for nonalcoholic fatty liver disease

Non-HDL cholesterol and LDL cholesterol in the dyslipidemic classification in patients with nonalcoholic fatty liver disease

Dietary and genetic determinants of non-alcoholic fatty liver disease in coronary heart disease patients

Incidence of liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease

Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease

Discordance Between Very Low-Density Lipoprotein Cholesterol and Low-Density Lipoprotein Cholesterol Increases Cardiovascular Disease Risk in a Geographically Defined Cohort

Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults

Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study.

Cardiac remodelling in non‐alcoholic fatty liver disease in the general population

Remnant cholesterol, stronger than triglycerides, is associated with incident non-alcoholic fatty liver disease

Biomedical consequences of elevated cholesterol-containing lipoproteins and apolipoproteins on cardiovascular and non-cardiovascular outcomes